Dosing & Uses
Dosage Forms & Strengths
pramoxine/mineral oil/zinc oxide rectal
topical ointment
- 1%/46.6%/12.5%
Topical Pain
For symptomatic relief of the discomfort associated with hemorrhoids, perianal itchin, or irritation
Apply externally to affected area up to 5 times daily PRN
Administration
When practical, cleanse the affected area with mild soap and warm water and rinse thoroughly and gently dry by patting or blotting with toilet tissue or a soft cloth before application
Clean dispensing cap after every use
Dosage Forms & Strengths
pramoxine/mineral oil/zinc oxide rectal
topical ointment
- 1%/46.6%/12.5%
Topical Pain
For symptomatic relief of the discomfort associated with hemorrhoids, perianal itching or irritation
<12 years: Safety and efficacy not established
≥12 years: Apply externally to affected area up to 5 times daily PRN
Administration
When practical, cleanse the affected area with mild soap and warm water and rinse thoroughly and gently dry by patting or blotting with toilet tissue or a soft cloth before application
Clean dispensing cap after every use
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (4)
- beta carotene
mineral oil decreases levels of beta carotene by drug binding in GI tract. Use Caution/Monitor.
- digoxin
mineral oil decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
- levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
mineral oil decreases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely.
- vitamin D
mineral oil will decrease the level or effect of vitamin D by Other (see comment). Use Caution/Monitor. Avoid concomitant use of mineral oil and vitamin D supplements to avoid risk of decreased absorption of vitamin D. Applies to only oral administration of these agents.
Minor (21)
- antithrombin alfa
mineral oil decreases levels of antithrombin alfa by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- antithrombin III
mineral oil decreases levels of antithrombin III by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- argatroban
mineral oil decreases levels of argatroban by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- bemiparin
mineral oil decreases levels of bemiparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- bivalirudin
mineral oil decreases levels of bivalirudin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- dabigatran
mineral oil decreases levels of dabigatran by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- dalteparin
mineral oil decreases levels of dalteparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- docusate
docusate increases levels of mineral oil by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- enoxaparin
mineral oil decreases levels of enoxaparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ethinylestradiol
mineral oil decreases levels of ethinylestradiol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- fondaparinux
mineral oil decreases levels of fondaparinux by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- heparin
mineral oil decreases levels of heparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- mestranol
mineral oil decreases levels of mestranol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- phenindione
mineral oil decreases levels of phenindione by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- protamine
mineral oil decreases levels of protamine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- sulfadiazine
mineral oil decreases levels of sulfadiazine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- sulfamethoxazole
mineral oil decreases levels of sulfamethoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- sulfisoxazole
mineral oil decreases levels of sulfisoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- vitamin A
mineral oil decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- vitamin E
mineral oil decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- vitamin K1 (phytonadione)
mineral oil decreases levels of vitamin K1 (phytonadione) by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Irritation
Pruritus
Warnings
Contraindications
Hypersensitivity
Cautions
For external use only
Do not use in the eyes
Do not use on blistered or broken skin
If condition worsens, or if symptoms persist for >7 days or clear up and occur again within a few days, discontinue and reassess therapy
Pregnancy & Lactation
Pregnancy Category: Undetermined, caution advised
Lactation: Unknown if excreted in breast milk, caution advised
Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Pramoxine: local anesthetic due to inhibition of conduction of nerve impulses from sensory nerves, resulting from an alteration of the cell membrane permeability to ions
Zinc oxide: antiseptic and protectant properties
Absorption
Minimal
Onset: 3-5 min
